A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Longterm Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Longterm Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2017

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms TRANSFIGURE
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 30 Nov 2017 Results published in a Novartis media release.
    • 30 Nov 2017 According to a Novartis media release, data from the study has been presented at the 8th International Congress of Psoriasis from Gene to Clinic 2017.
    • 05 May 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top